{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:41:14Z","timestamp":1789684874264,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-024-03840-7","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T10:52:13Z","timestamp":1737197533000},"page":"3073-3083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PMN-MDSCs are responsible for immune suppression in anti-PD-1 treated TAP1 defective melanoma"],"prefix":"10.1007","volume":"27","author":[{"given":"Xiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengrui","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3163-6068","authenticated-orcid":false,"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"issue":"3","key":"3840_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133\u201350.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"3840_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660\u20139.","journal-title":"Cell Res"},{"issue":"5","key":"3840_CR3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"1","key":"3840_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12885-022-10491-w","volume":"23","author":"Z Tu","year":"2023","unstructured":"Tu Z, Li K, Ji Q, Huang Y, Lv S, Li J, et al. Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. BMC Cancer. 2023;23(1):133.","journal-title":"BMC Cancer"},{"key":"3840_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer immune evasion through loss of MHC class I antigen presentation. Front Immunol. 2021;12: 636568.","journal-title":"Front Immunol"},{"issue":"8","key":"3840_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1136\/jitc-2021-002899","volume":"9","author":"A Hazini","year":"2021","unstructured":"Hazini A, Fisher K, Seymour L, Guerder S, Flavell RA. Deregulation of HLA-I in cancer and its central importance for immunotherapy T-cell activation. Two for T. J Immunother Cancer. 2021;9(8):866\u20138.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"3840_CR7","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828\u201335.","journal-title":"Nat Med"},{"issue":"6","key":"3840_CR8","doi-asserted-by":"publisher","first-page":"1259.e1211","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259.e1211-1271.e1211.","journal-title":"Cell"},{"issue":"10151","key":"3840_CR9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet (London, England). 2018;392(10151):971\u201384.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"3840_CR10","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"key":"3840_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","volume":"63","author":"RP Tobin","year":"2018","unstructured":"Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018;63:282\u201391.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"3840_CR12","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.apsb.2019.09.006","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q, et al. Epigenetic strategies synergize with PD-L1\/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020;10(5):723\u201333.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"3840_CR13","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","volume":"23","author":"ST Barry","year":"2023","unstructured":"Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP. Therapeutic targeting of tumour myeloid cells. Nat Rev Cancer. 2023;23(4):216\u201337.","journal-title":"Nat Rev Cancer"},{"key":"3840_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.990463","volume":"13","author":"H Sui","year":"2022","unstructured":"Sui H, Dongye S, Liu X, Xu X, Wang L, Jin CQ, et al. Immunotherapy of targeting MDSCs in tumor microenvironment. Front Immunol. 2022;13: 990463.","journal-title":"Front Immunol"},{"issue":"5","key":"3840_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/cells12050789","volume":"12","author":"K Tomela","year":"2023","unstructured":"Tomela K, Pietrzak B, Galus \u0141, Mackiewicz J, Schmidt M, Mackiewicz AA, et al. Myeloid-derived suppressor cells (MDSC) in melanoma patients treated with anti-PD-1 immunotherapy. Cells. 2023;12(5):789.","journal-title":"Cells"},{"key":"3840_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005002","author":"AM Cornel","year":"2022","unstructured":"Cornel AM, Dunnebach E, Hofman DA, Das S, Sengupta S, van den Ham F, et al. Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. J Immunother Cancer. 2022. https:\/\/doi.org\/10.1136\/jitc-2022-005002.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"3840_CR17","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1007\/s00262-023-03497-1","volume":"72","author":"SH Sun","year":"2023","unstructured":"Sun SH, Angell CD, Savardekar H, Sundi D, Abood D, Benner B, et al. BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy. Cancer Immunol Immunother. 2023;72(11):3461\u201374.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"3840_CR18","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1158\/1541-7786.MCR-20-0652","volume":"19","author":"X Zhang","year":"2021","unstructured":"Zhang X, Sabio E, Krishna C, Ma X, Wang J, Jiang H, et al. Qa-1b modulates resistance to anti\u2013PD-1 immune checkpoint blockade in tumors with defects in antigen processing. Mol Cancer Res. 2021;19(6):1076\u201384.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"3840_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184.","journal-title":"Mol Cancer"},{"issue":"1","key":"3840_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2019.12.003","volume":"64","author":"M Del Val","year":"2020","unstructured":"Del Val M, Ant\u00f3n LC, Ramos M, Mu\u00f1oz-Abad V, Campos-S\u00e1nchez E, Sun L, et al. Endogenous TAP-independent MHC-I antigen presentation: not just the ER lumen clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis. Curr Opin Immunol. 2020;64(1):9\u201314.","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"3840_CR21","doi-asserted-by":"publisher","first-page":"812.e814","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou TH, et al. The immune landscape of cancer. Immunity. 2018;48(4):812.e814-830.e814.","journal-title":"Immunity"},{"key":"3840_CR22","first-page":"10","volume":"2019","author":"J Bi","year":"1999","unstructured":"Bi J, Tian Z. NK cell dysfunction and checkpoint immunotherapy. Front Immunol. 1999;2019:10.","journal-title":"Front Immunol"},{"issue":"3","key":"3840_CR23","doi-asserted-by":"publisher","first-page":"a028480","DOI":"10.1101\/cshperspect.a028480","volume":"11","author":"E Alspach","year":"2019","unstructured":"Alspach E, Lussier DM, Schreiber RD. Interferon \u03b3 and Its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb Perspect Biol. 2019;11(3):a028480.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"10","key":"3840_CR24","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138.","journal-title":"Nat Med"},{"key":"3840_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104254","volume":"359","author":"R Weber","year":"2021","unstructured":"Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, et al. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol. 2021;359: 104254.","journal-title":"Cell Immunol"},{"issue":"2","key":"3840_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00262-019-02388-8","volume":"69","author":"S Ostrand-Rosenberg","year":"2020","unstructured":"Ostrand-Rosenberg S, Beury DW, Parker KH, Horn LA. Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment. Cancer Immunol Immunother. 2020;69(2):215\u201321.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"3840_CR27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485\u201398.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"3840_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.617335","volume":"11","author":"Y Lei","year":"2021","unstructured":"Lei Y, Li X, Huang Q, Zheng X, Liu M, Lauvau G, et al. Progress and challenges of predictive biomarkers for immune checkpoint blockade human transporters associated with antigen processing (TAPs) select epitope precursor peptides for processing in the endoplasmic reticulum and presentation to T cells. Front Oncol. 2021;11(9): 617335.","journal-title":"Front Oncol"},{"issue":"1","key":"3840_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2326-6066.CIR-19-0398","volume":"8","author":"J Han","year":"2020","unstructured":"Han J, Duan J, Bai H, Wang Y, Wan R, Wang X, et al. TCR repertoire diversity of peripheral PD-1(+)CD8(+) T cells predicts clinical outcomes after immunotherapy in patients with non-small cell lung cancer. Cancer Immunol Res. 2020;8(1):146\u201354.","journal-title":"Cancer Immunol Res"},{"key":"3840_CR30","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.3389\/fimmu.2020.01276","volume":"11","author":"EM Muntjewerff","year":"2020","unstructured":"Muntjewerff EM, Meesters LD, van den Bogaart G. Antigen cross-presentation by macrophages. Front Immunol. 2020;11:1276.","journal-title":"Front Immunol"},{"issue":"9","key":"3840_CR31","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00109-021-02088-w","volume":"99","author":"A Tabassum","year":"2021","unstructured":"Tabassum A, Samdani MN, Dhali TC, Alam R, Ahammad F, Samad A, et al. Transporter associated with antigen processing 1 (TAP1) expression and prognostic analysis in breast, lung, liver, and ovarian cancer. J Mol Med (Berl). 2021;99(9):1293\u2013309.","journal-title":"J Mol Med (Berl)"},{"issue":"5","key":"3840_CR32","first-page":"2771","volume":"35","author":"K Segami","year":"2021","unstructured":"Segami K, Aoyama T, Hiroshima Y, Komori K, Hashimoto I, Watanabe H, et al. Clinical significance of TAP1 and DLL4 expression in patients with locally advanced gastric cancer. In Vivo (Athens, Greece). 2021;35(5):2771\u20137.","journal-title":"In Vivo (Athens, Greece)"},{"key":"3840_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001643corr1","author":"MA Ghonim","year":"2021","unstructured":"Ghonim MA, Ibba SV, Tarhuni AF, Errami Y, Luu HH, Dean MJ, et al. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001643corr1.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"3840_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12943-020-1144-6","volume":"19","author":"D Ren","year":"2020","unstructured":"Ren D, Hua Y, Yu B, Ye X, He Z, Li C, et al. Predictive biomarkers and mechanisms underlying resistance to PD1\/PD-L1 blockade cancer immunotherapy. Mol Cancer. 2020;19(1):19.","journal-title":"Mol Cancer"},{"issue":"3","key":"3840_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.12.010","volume":"13","author":"L Barrueto","year":"2020","unstructured":"Barrueto L, Caminero F, Cash L, Makris C, Lamichhane P, Deshmukh RR, et al. Resistance to checkpoint inhibition in cancer immunotherapy CD8(+) T cell states in human cancer: insights from single-cell analysis. Transl Oncol. 2020;13(3): 100738.","journal-title":"Transl Oncol"},{"issue":"1","key":"3840_CR36","doi-asserted-by":"publisher","first-page":"15767","DOI":"10.1038\/s41598-019-52414-z","volume":"9","author":"J Yao","year":"2019","unstructured":"Yao J, Gong Y, Zhao W, Han Z, Guo S, Liu H, et al. Comprehensive analysis of POLE and POLD1 gene variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Sci Rep. 2019;9(1):15767.","journal-title":"Sci Rep"},{"issue":"4","key":"3840_CR37","doi-asserted-by":"publisher","first-page":"825.e818","DOI":"10.1016\/j.cell.2017.12.026","volume":"172","author":"MF Tavazoie","year":"2018","unstructured":"Tavazoie MF, Pollack I, Tanqueco R, Ostendorf BN, Reis BS, Gonsalves FC, et al. LXR\/ApoE activation restricts innate immune suppression in cancer. Cell. 2018;172(4):825.e818-840.e818.","journal-title":"Cell"},{"issue":"12","key":"3840_CR38","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/eji.202048666","volume":"50","author":"E Tavukcuoglu","year":"2020","unstructured":"Tavukcuoglu E, Horzum U, Yanik H, Uner A, Yoyen-Ermis D, Nural SK, et al. Human splenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) are strategically located immune regulatory cells in cancer. Eur J Immunol. 2020;50(12):2067\u201374.","journal-title":"Eur J Immunol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03840-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03840-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03840-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T14:35:23Z","timestamp":1750343723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03840-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["3840"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03840-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"2 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal experiments were approved by the Animal Care and Use Committee of Guangzhou First People\u2019s Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"No human subjects are  included in this study. Informed consent is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}